explore -WSS

explore

author：fashion 2025-09-28 16:35:16 - browse：3364

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Micronoma's microbiome cancer diagnostic approach under fire

focus

WSS

Adults seen as increasingly susceptible to measles

What to make of Biden’s latest efforts on cancer research

Walmart eyes Medicare Advantage provider ChenMed

NIH launches clinical trials and new research office for long Covid

Private equity could exacerbate cardiology's overuse problem, experts fear

Will the IRA bring competition to the biologics market?

hotspot

explore

focus

Apple is now the first public company to be valued at $3 trillion

Sage hopes for a blockbuster in antidepressant now before FDA

Moonlake's readout produced a cash windfall. Risks remain

What the airline industry can learn from medicine

In age of alternative facts, a scholarly course on calling out crap

New safety details link Apellis eye drug to rare cases of blindness

Walensky prepares to leave CDC — and Congress — behind

Walmart eyes Medicare Advantage provider ChenMed

How one medical school became remarkably diverse

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

hotspot

Acelyrin, a rare IPO success, stumbles in its first big test

New weight loss drugs vying to be the next Wegovy or Mounjaro

New weight loss drugs vying to be the next Wegovy or Mounjaro

PEPFAR is under serious threat — and so is global health

‘Oppenheimer’ and the risks of AI in health care

What the US credit downgrade means for the economy, your finances

focus

focus

leisure time

hotspot